Skip to main content

Table 4 Summary of best response by age and prognostic group categories (FAS)

From: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study

 

Overall response rate

n (%)

Complete response

n (%)

Partial response

n (%)

Stable disease

n (%)

Progressive disease

n (%)

MSKCC risk categories (n = 93)

 Favourable (n = 12)

7 (58.3)

1 (8.3)

6 (50.0)

5 (41.7)

0

 Intermediate (n = 69)

18 (26.1)

2 (2.9)

16 (23.2)

30 (43.5)

21 (30.4)

 Poor (n = 12)

0

0

0

5 (41.7)

7 (58.3)

IMDC risk categories (n = 80)

 Favourable (n = 8)

4 (50.0)

0

4 (50.0)

4 (50.0)

0

 Intermediate (n = 61)

16 (26.2)

2 (3.3)

14 (22.9)

26 (42.6)

19 (31.1)

 Poor (n = 11)

1 (9.1)

0

1 (9.1)

4 (36.3)

6 (54.5)

Age categories (n = 127)

  < 65 years (n = 80)

22 (27.5)

3 (3.8)

19 (23.7)

33 (41.3)

25 (31.2)

  ≥ 65 years (n = 47)

9 (19.1)

1 (2.1)

8 (17.0)

23 (48.9)

15 (31.9)

  1. FAS full analysis set, IMDC International Metastatic Renal Cell Carcinoma Database Consortium, MSKCC Memorial Sloan Kettering Cancer Center, Overall response rate = CR + PR